# A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

> **NCT00051116** · PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 100 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-5013

## Key facts

- **NCT ID:** NCT00051116
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2009-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051116, "A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00051116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*